HIV-1 induces cytoskeletal alterations and Rac1 activation during monocyte-blood–brain barrier interactions: modulatory role of CCR5

Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation

(2013) Julieta Díaz-Delfín et al.   CYTOKINE

Glycogen Synthase Kinase 3β Inhibition Prevents Monocyte Migration across Brain Endothelial Cells via Rac1-GTPase Suppression and Down-Regulation of Active Integrin Conformation

(2012) Slava Rom et al.   AMERICAN JOURNAL OF PATHOLOGY

In vitro effects of the CCR5 inhibitor maraviroc on human T cell function

(2012) H. Arberas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Correlation of coreceptor usage and disease progression

(2012) Chris Verhofstede et al.   Current Opinion in HIV and AIDS

In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells

(2011) R. Rossi et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial

(2011) A. MacInnes et al.   HIV CLINICAL TRIALS

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study

(2011) L. Garvey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient

(2011) J. Symons et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection

(2011) Pasqua Gramegna et al.   PLoS One

Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms

(2010) Giovanna Melica et al.   AIDS

Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected Patients

(2010) Juan Manuel Tiraboschi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Maraviroc Concentrations in Seminal Plasma in HIV-Infected Patients

(2010) Juan Manuel Tiraboschi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Downregulation of Leukocyte Migration After Treatment With CCR5 Antagonist Maraviroc

(2010) Raffaella Rossi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Cross-talk between STAT1 and PI3K/AKT signaling in HIV-1-induced blood-brain barrier dysfunction: Role of CCR5 and implications for viral neuropathogenesis

(2010) Bo Yang et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Establishment of primary cultures of human brain microvascular endothelial cells to provide an in vitro cellular model of the blood-brain barrier

(2010) Michael J Bernas et al.   Nature Protocols

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients

(2009) Aylin Yilmaz et al.   AIDS

Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?

(2009) Guillaume Martin-Blondel et al.   AIDS

The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function

(2009) Jia Ni et al.   BRITISH JOURNAL OF PHARMACOLOGY

Serine-71 phosphorylation of Rac1/Cdc42 diminishes the pathogenic effect ofClostridium difficiletoxin A

(2009) Janett Schoentaube et al.   CELLULAR MICROBIOLOGY

Maraviroc, a CCR5 Coreceptor Antagonist That Blocks Entry of Human Immunodeficiency Virus Type 1

(2009) Joshua S Hunt et al.   PHARMACOTHERAPY

Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection

(2008) Sharon S. Lieberman-Blum et al.   CLINICAL THERAPEUTICS

Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation

(2008) I. Ayala et al.   JOURNAL OF CELL SCIENCE

Rac1 GTPase is activated by hepatitis B virus replication — involvement of HBX

(2007) Tuan Lin Tan et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH